- Home
- BLNK vs ABOS Comparison
BLNK vs ABOS Comparison
Compare BLNK & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- ABOS
- Stock Information
- Founded
- BLNK 2009
- ABOS 1996
- Country
- BLNK United States
- ABOS United States
- Employees
- BLNK N/A
- ABOS N/A
- Industry
- BLNK Industrial Specialties
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- ABOS Health Care
- Exchange
- BLNK Nasdaq
- ABOS Nasdaq
- Market Cap
- BLNK 129.3M
- ABOS 113.9M
- IPO Year
- BLNK N/A
- ABOS 2021
- Fundamental
- Price
- BLNK $1.91
- ABOS $2.19
- Analyst Decision
- BLNK Buy
- ABOS Strong Buy
- Analyst Count
- BLNK 8
- ABOS 3
- Target Price
- BLNK $2.54
- ABOS $8.00
- AVG Volume (30 Days)
- BLNK 7.1M
- ABOS 472.2K
- Earning Date
- BLNK 11-07-2025
- ABOS 11-11-2025
- Dividend Yield
- BLNK N/A
- ABOS N/A
- EPS Growth
- BLNK N/A
- ABOS N/A
- EPS
- BLNK N/A
- ABOS N/A
- Revenue
- BLNK $104,788,000.00
- ABOS N/A
- Revenue This Year
- BLNK N/A
- ABOS N/A
- Revenue Next Year
- BLNK $19.30
- ABOS N/A
- P/E Ratio
- BLNK N/A
- ABOS N/A
- Revenue Growth
- BLNK N/A
- ABOS N/A
- 52 Week Low
- BLNK $0.63
- ABOS $0.86
- 52 Week High
- BLNK $2.65
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- BLNK 53.02
- ABOS 59.21
- Support Level
- BLNK $1.69
- ABOS $1.85
- Resistance Level
- BLNK $1.93
- ABOS $2.35
- Average True Range (ATR)
- BLNK 0.19
- ABOS 0.21
- MACD
- BLNK -0.06
- ABOS -0.01
- Stochastic Oscillator
- BLNK 22.77
- ABOS 56.36
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.